SCHEMBL16489012

SCHEMBL16489012

O=C(O)c1ccccc1Nc1cc(Cl)ccc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.66
ALK Q9UM73 1/20 0.66
GRIK1 P39086 6/20 0.64
CYP2C9 P11712 2/20 0.62
CXCL8 P10145 1/20 0.62
FTO Q9C0B1 3/20 0.61
PBRM1 Q86U86 1/20 0.60
TTR P02766 3/20 0.59
MEN1 O00255 2/20 0.59
ADORA3 P0DMS8 2/20 0.59
PTGS2 P35354 2/20 0.59
AKR1C3 P42330 2/20 0.59
KMT2A Q03164 2/20 0.59
USP2 O75604 1/20 0.59
MT-CO2 P00403 1/20 0.59
LMNA P02545 1/20 0.59
PLA2G1B P04054 1/20 0.59
CYP1A2 P05177 1/20 0.59
PGR P06401 1/20 0.59
CYP3A4 P08684 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lobenzarit SCHEMBL187951 0.90 GRIK1 (0.63) GRIK1CYP2C9FTOPBRM1TTR
Lobenzarit SCHEMBL30753983 0.90 GRIK1 (0.63) GRIK1CYP2C9FTOPBRM1TTR
SCHEMBL6140792 0.89 FABP4 (0.62) GRIK1CYP2C9FTOPBRM1TTR
Lobenzarit SCHEMBL7935 0.89 GRIK1 (0.61) GRIK1CYP2C9FTOPBRM1TTR
Lobenzarit SCHEMBL1479150 0.89 GRIK1 (0.61) GRIK1CYP2C9FTOPBRM1TTR
Lobenzarit SCHEMBL29453054 0.89 GRIK1 (0.61) GRIK1CYP2C9FTOPBRM1TTR
Lobenzarit SCHEMBL9621335 0.89 GRIK1 (0.61) GRIK1CYP2C9FTOPBRM1TTR
SCHEMBL24021599 0.87 LMNA (0.62) GRIK1CYP2C9FTOPBRM1TTR
SCHEMBL14576292 0.87 GRIK1 (0.73) GRIK1CYP2C9CXCL8FTOPBRM1
SCHEMBL30611313 0.87 GRIK1 (0.73) GRIK1CYP2C9CXCL8FTOPBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11173137-B2 Compositions and methods to modulate chloride ion channel activity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-11-16 US disclosed
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION CHOUDHARY MUHAMMAD IQBAL (PK) 2015-02-19 US disclosed
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION CHOUDHARY MUHAMMAD IQBAL (PK) 2015-02-19 US disclosed
US-20150030539-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PIRAMAL IMAGING SA (CH) 2015-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION AGER, NFKBIA, DNPEP EGFR 1218/4885ALK 1556/4885GRIK1 2669/4885
US-20150030539-A1 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS PMP22, MEN1, VHL EGFR 609/4885ALK 618/4885GRIK1 298/4885
US-11173137-B2 Compositions and methods to modulate chloride ion channel activity CLCN2, CLIC1, CLIC4 EGFR 4489/4885ALK 4528/4885GRIK1 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.